Creganna is pursuing development of a highly engineered Micromuscle-brand biomaterial that can change volume in response to an electrical stimulus, typically 1-2 volts. The material can be incorporated into a range of medical devices.
Functions of the advanced biocompatible electrically conductive polymers include controlled movement swelling or contracting and controlled release, said Alan Crean, business developer with Creganna, during a news conference in Anaheim.
Academics at LinkÃ¶ping University in LinkÃ¶ping, Sweden, began the concept development decades ago and formed Micromuscle AB in 2000, said Magnus Krogh, Creganna new technologies representative.
Galway, Ireland-based Creganna acquired Micromuscle technology and assets in October 2008, after a venture investor withdrew and forced the LinkÃ¶ping-based company to seek voluntary liquidation.
Creganna employs 470 in Ireland and another 50 in a 30,000-square-foot Marlborough, Mass., extrusion and braiding facility.